News
BIOCORP and Merck KGaA, Darmstadt, Germany, Sign a New Partnership for Smart Drug Delivery
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, and
Valbiotis Accelerates Its Marketing Strategy
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Valbiotis forciert seine Marketingstrategie
Valbiotis (FR0013254851 – ALVAL, PEA / SME förderfähig), ein Unternehmen für Forschung und Entwicklung, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von Stoffwechsel-
Sensorion to Present at the European Society of Gene & Cell Therapy (ESGCT) and the Gene Therapy for Rare Disorders Europe conferences in October 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
BILENDI: Very strong growth in results for H1 2022
UV GERMI chosen by EPUR (Veolia) to equip its new dedicated wastewater reuse units
Median Technologies Announces Formation of Clinical Advisory Board for iBiopsy® Lung Cancer Screening
Regulatory News:
Median Technologies (Paris:ALMDT) announced today the formation of their Clinical Advisory Board (CAB) for iBiopsy® Lung Cancer Screening. This group of world class physicians
Pharnext announces a reverse stock split and suspension of the right to exercise all the securities giving access to Pharnext's share capital including the conversions of convertible bonds
Pharnext executes a financing agreement with Néovacs for EUR 20.7 million net to further develop PXT3003 for Charcot-Marie-Tooth disease type 1A
Valbiotis präsentiert weitere positive Ergebnisse aus der klinischen HEART-Studie zu TOTUM•070 gegen Hypercholesterinämie
Valbiotis (FR0013254851 – ALVAL, qualifiziert für PEA/SME) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung
Valbiotis Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Sensorion to Participate in Various Upcoming Investor Conferences
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Sensorion Reports 2022 First Half Results
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
BIOCORP gibt anlässlich der EASD-Jahrestagung die CE-Kennzeichnung von SoloSmart® bekannt, einem medizinischen Hilfsmittel für SANOFI Solostar®-Pens
fcAufsichtsrechtliche Meldungen:
BIOCORP (FR0012788065 – ALCOR / PEA‐PME-qualifiziert), ein französisches Unternehmen, das auf die Konzeption, Entwicklung und Herstellung von innovativen
BIOCORP announces the CE marking of SoloSmart®, an accessory medical device for SANOFI Solostar® pens at the occasion of EASD
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, and SANOFI announced
Valbiotis informiert über seine Fortschritte und veröffentlicht seinen Finanzbericht für das erste Halbjahr 2022
Valbiotis (FR0013254851 – ALVAL/PEA/KMU-berechtigt) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von
Valbiotis Provides an Update on Its Progress and Publishes Its Financial Report for the First Half of 2022
Regulatory News:
Valbiotis (FR0013254851 – ALVAL / PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic
Pharnext: Findings on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A From ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the American Association of Neuromuscular & Electrodia
Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation
Regulatory News:
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Pharnext: Findings From ‘Real-World’ Digital Lifestyle Study, CMT&Me, on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A Published in the Journal of Clinical Neuromuscular Disease
MYHOTELMATCH: PERFORMANCE AND INITIAL FIGURES 2022
Sensorion Receives Positive Opinion for Orphan Drug Designation for OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss From the European Medicine Agency
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial
Sensorion to participate in the Inner Ear Biology Workshop in September 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Median Technologies to Participate in the 2022 ESMO Congress, Sep 9 – 13, 2022, Paris, France, With Two Scientific Posters on iCRO and iBiopsy®
Regulatory News:
Median Technologies (ALMDT) (Paris:ALMDT) announced today that the Company will be participating in the 2022 ESMO (European Society for Medical Oncology) Congress, to be held in